Article Text

PDF

PS-042c Is Low-dose Combined Oral Contraceptives Use Associated To Lower Bone Mineral Content Variation In Adolescents Over A One-year Period?
  1. TB Goldberg1,
  2. TP Biason1,
  3. CS Kurokawa2,
  4. MR Moretto2,
  5. AS Teixeira3,
  6. HRC Nunes4
  1. 1Department of Pediatrics – Adolescent Medicine Course – Graduate Program in Gynecology Obstetrics and Mastology, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil
  2. 2Clinical and Experimental Pediatrics Research Center – Department of Pediatrics, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil
  3. 3Department of Tropical Diseases and Diagnostic Imaging, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil
  4. 4Statistical Consultant, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil

Abstract

Background Low dose combined oral contraceptives (COC) can interfere in bone mass acquisition during adolescence. To evaluate bone mineral density (BMD) and bone mineral content (BMC) in female adolescents taking a standard low-dose (EE 20 µg/Desogestrel 150 µg) combination oral contraceptive (COC) over a one-year period and compare with healthy adolescents from the same age group not taking COCs.

Methods A non-randomised parallel control study with one-year follow-up. Sixty-seven adolescents from 12 to 20 years of age, divided into COC users (n = 41) taking 20 µg EE/150 µg Desogestrel and non-user controls (n = 26), were evaluated through bone densitometry examinations at baseline and 12 months later. Comparisons between groups at study start was done through the Mann-Whitney test with significance level fixed at 5% or corresponding p value; comparisons between groups at study start and 12 months later used variations in median percentages for bone mass variables.

Results COC users presented low bone mass acquisition in the lumbar spine and BMD and BMC median variations between baseline and at 12 months of 2.07% and +1.57% respectively whereas the control group presented variations of +12.16% and +16.84% for BMD and BMC, respectively, over the same period. The total body BMD and BMC presented similar evolution during the study in both groups. Statistical significance (p

Conclusion The use of a low COC dose (EE 20 µg/Desogestrel 150 µg) was associated to lower bone mass acquisition in adolescents during the study period.

Trial registration: (Register Number):RBR-5 h9b3c.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.